CNS Pharmaceuticals, Inc. (CNSP): Capital Expenditures
$18.2K
Year ended 2025-12-31
$28.2K
Trailing 12 months to 2026-06-30
+60.2%
3-year compound annual growth
+0.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.2K | +334.0% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $4.2K | +7.4% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $3.9K | -11.8% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $4.4K | -23.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $5.7K | -68.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $17.9K | -10.8% | 2021-02-12, From 2020-01-01 |
| 2019-12-31 | $20.1K | n/a | 2021-02-12, From 2019-01-01 |
| 2018-12-31 | $0 | n/a | 2020-03-12, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $18.2K | +334.0% |
| GRI Bio, Inc. (GRI) | 2025-12-31 | $3.0K | n/a |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $112.0K | -18.8% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $756.6K | +0.5% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $5.9K | n/a |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $2.0K | -60.0% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2024-12-31 | $3.2K | +16.9% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $262.0K | +42.4% |
Compare CNSP, GRI, PTN, IGC side by side · Screen every company in Pharmaceutical Preparations ↗